This roundtable series considers the operationalization of care for patients with relapsed/refractory multiple myeloma, as discussed by key opinion leaders and participants at virtual live events.
Tolerability of Teclistamab Improved with Step-Up Dosing
In a discussion with Targeted Oncology, David Dingli, MD, PhD, looks at how the use of step-up dosing with tecalistimab helped avoid many serious adverse events.
Developing Standard Operating Procedures for Using Bispecific Agents
During a Case-Based Roundtable event, Robert Mancini, PharmD, BCOP, FHOPA, discusses his experience setting up procedures for administering bispecific T-cell engagers for a large community oncology practice. This is the first of 2 articles based on this event.
2 Clarke Drive Cranbury, NJ 08512